Ulcerative Colitis Research Services

Ulcerative colitis (UC) is a chronic disorder characterized by inflammation of the mucosa and sub-mucosa of the colon and rectum lining, causing ulcers to develop. It is usually possible to notice a clear margin between normal and affected intestinal tissue. There has been a global increase in UC incidence. Although much research is spent on understanding its pathophysiology, the exact aetiology is still unknown. The main goals of UC therapy are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications and improve quality of life, also avoiding disability. The therapeutic strategies of UC are usually guided by the severity (mild, moderate, severe) and extent (proctitis, left-sided colitis, pancolitis) of disease.

Fig. 1. An in-depth understanding of cross-sectional crypt structure of the large intestine can help develop effective treatments for ulcerative colitis. Fig. 1. The cross-sectional crypt structure of the large intestine and current UC therapeutic strategies. (Kaur et al., 2020)

Explore Our Expertise in Ulcerative Colitis

As a full-service CRO, we have extensive expertise in preclinical UC research. Our team of experts will guide you through the study design process, ensuring that scientific questions are addressed and the appropriate experimental model is used.

Ulcerative Proctitis Research Services

Ace Therapeutics provides reliable animal models to support your drug discovery and preclinical development programs for ulcerative proctitis. Using technologies such as genomics, transcriptomics, proteomics, flow cytometry, and metabolomics, we help our clients discover new targets for ulcerative proctitis.

Left-sided Colitis Research Services

Ace Therapeutics focuses on utilizing reliable animal models of IBD to help clients understand the complex mechanisms of left-sided colitis and accelerate the development of your therapies. Our ability to provide multi-faceted outcome studies means that you will have the data that best fits your drug discovery program.

Extensive Colitis Research Services

Ace Therapeutics provides customized preclinical research for extensive colitis, supporting the advancement of your program. Leveraging our translational research expertise, broad-range of assays, animal models, and customized approach, we provide superior preclinical research support for your program to address the unique challenges posed by these conditions.

Customized Preclinical Ulcerative Colitis Study Design for Your Therapy

Ace Therapeutics is committed to providing clients with reliable experimental models and cutting-edge analytical platforms to advance drug discovery and development for UC. Whether it is for individual projects, in conjunction with preclinical research models or drug efficacy assessment services, our technologies are designed to accelerate drug development.

Specific Animal Models for UC

Chemically induced models such as DSS, TNBS/DNBS, oxazolone, acetic acid, indomethacin.
Immunologic models such as 2, 4-Dinitrochlorobenzene (DNCB).
Bacterial induced models such as salmonella, adherent invasive E. coli.
Genetically engineered models such as TGF-b -/-, IL-2 -/-, MDR1A -/-, TCRa -/-, XBP1 -/-, NEMO -/-.
Transgenic mouse models such as IL-7 Tg mice.
Adoptive transfer models such as CD45RB^high transfer model.

Comprehensive Preclinical Ulcerative Colitis Research

We provide comprehensive preclinical ulcerative colitis services through these animal models. Whether it is basic mechanistic or translational research, our leading scientists will assist in the design and execution of your study from inception to completion.

UC pathomechanism study
Discover new targets for UC
Drug efficacy evaluation
ADME/DMPK studies
Drug safety testing
UC biomarker development

Ace Therapeutics' industry-leading IBD models and comprehensive assessments provide deep insights that advance your preclinical UC research to the clinical development stage. Partner with us to unlock the potential of your program and advance your therapies. Please do not hesitate to contact us.

Reference

Kaur, A., et al. (2020). Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. Journal of inflammation, 17, 1-8.

! For research use only, not intended for any clinical use.